ERAS-601 is under clinical development by Erasca and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ERAS-601’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ERAS-601 is under development for the treatment of solid tumor, metastatic colorectal cancer (CRC) and human papillomavirus (HPV)-negative advanced head and neck squamous cell carcinoma and non-small cell lung cancer. The drug candidate is administered through oral route. It acts by targeting SHP2 (Src Homology-2 phosphatase).
Erasca is an oncology drug development company that uses its artificial intelligence drug discovery platform to treat and cure cancer. The company is headquartered in San Diego, California, the US.
For a complete picture of ERAS-601’s drug-specific PTSR and LoA scores, buy the report here.